Literature DB >> 25144217

Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension.

Andrea Frustaci1, Nicola Petrosillo, Dario Vizza, Marco Francone, Roberto Badagliacca, Romina Verardo, Francesco Fedele, Giuseppe Ippolito, Cristina Chimenti.   

Abstract

BACKGROUND: Right ventricle compromise affects survival of patients with HIV-associated pulmonary artery hypertension (PAH).
DESIGN: Myocardial histology with viral assessment may clarify the mechanism of right ventricular deterioration and provide clues on PAH origin.
METHODS: Fifteen patients with HIV infection, PAH and right ventricular dysfunction underwent cardiac magnetic resonance, catheterization, coronary with ventricular angiography and biventricular endomyocardial biopsy. Endothelial expression of HLA-DR, ICAM-1, E-selectin and VCAM-1 was semi-quantitatively evaluated. PCR for HIV, hepatitis C virus, human herpes virus-6, human herpes virus-8, Epstein-Barr virus, adenovirus, cytomegalovirus, enterovirus, influenza A/B and parvovirus B19 was performed. In PCR-positive hearts, viral protein adenovirus-1 and TORDJI-22 were assessed by immunohistology.
RESULTS: New York Heart Association class was 2.4 ± 0.5, mean pulmonary artery pressure 49.93 ± 10.15 mmHg and wedge pressure 9.5 ± 2.19 mmHg. Coronaries were normal with slow flow. Left ventricular and/or right ventricular micro-aneurysms were seen in eight patients. Cardiac magnetic resonance documented increased right ventricular end-diastolic volume with reduced ejection fraction, normal left ventricular end-diastolic volume and left ventricular ejection fraction. Subepicardial/mesocardial oedema and delayed enhancement in the inter-ventricular junction and/or left ventricular inferolateral wall was detected in eight patients. Histology showed active lymphocytic myocarditis in 12 patients, with microvasculitis in three. Endothelial adhesion molecules were over-expressed in all patients. PCR was positive in four patients for hepatitis C virus and in two for adenovirus, and viruses localized both in cardiomyocytes and endothelial cells.
CONCLUSIONS: Inflammation/infection of myocardium and intramural vessels is detectable in patients with HIV-associated PAH. It may adversely affect right ventricular function and have a role in the compromised pulmonary circulation.

Entities:  

Mesh:

Year:  2014        PMID: 25144217     DOI: 10.1097/QAD.0000000000000426

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology.

Authors:  Joshua A Walker; Andrew D Miller; Tricia H Burdo; Michael S McGrath; Kenneth C Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

2.  Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review.

Authors:  Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah
Journal:  JAMA       Date:  2022-09-13       Impact factor: 157.335

3.  Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS.

Authors:  Joshua A Walker; Graham A Beck; Jennifer H Campbell; Andrew D Miller; Tricia H Burdo; Kenneth C Williams
Journal:  J Am Heart Assoc       Date:  2015-07-16       Impact factor: 5.501

Review 4.  Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.

Authors:  Kyle A Batton; Christopher O Austin; Katelyn A Bruno; Charles D Burger; Brian P Shapiro; DeLisa Fairweather
Journal:  Biol Sex Differ       Date:  2018-04-18       Impact factor: 5.027

Review 5.  The right treatment for the right ventricle.

Authors:  Joanne A Groeneveldt; Frances S de Man; Berend E Westerhof
Journal:  Curr Opin Pulm Med       Date:  2019-09       Impact factor: 3.155

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.